About Aria Pharmaceuticals
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Aria Pharmaceuticals's Product Videos
Expert Collections containing Aria Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aria Pharmaceuticals is included in 1 Expert Collection, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Latest Aria Pharmaceuticals News
Jul 31, 2023
IBM Watson, Benevolent AI, Atomwise, Exscientia, GNS Healthcare, Aria Pharmaceuticals, Euretos, Insitro, Cyclica, Insilico Medicine, and Iktos among others, are some of the key players operating in the market. July 31, 2023 11:05 ET Mumbai, INDIA Brooklyn, New York, July 31, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Artificial Intelligence in Oncology Drug Discovery Market is projected to grow at a CAGR of 30.2% from 2023 to 2028. The ever-growing volume of cancer-related data, rising demand for AI-driven tools and platforms within the oncology pharmaceutical space, and enormous investment in advanced technologies such as machine learning and natural language processing are some key factors that are driving market revenue. Key Market Insights As per the application outlook, the drug design and optimization segment is expected to be the highest revenue-generating segment in the artificial intelligence in oncology drug discovery market Based on the component outlook, the software & services segment is estimated to dominate the global market in terms of revenue generation Among the end-users, pharmaceutical companies & biotechnology companies are estimated to capture the maximum revenue share in the market North America (the United States, Canada, and Mexico) market is estimated to account for a major revenue share in the global artificial intelligence in oncology drug discovery market from 2023 to 2028 The Asia Pacific region is expected to serve as the fastest revenue-generating market during the forecast period IBM Watson, Benevolent AI, Atomwise, Exscientia, GNS Healthcare, Aria Pharmaceuticals, Euretos, Insitro, Cyclica, Insilico Medicine, and Iktos among others, are some of the key players in the artificial intelligence in oncology drug discovery market Request for a sample copy of the report @ https://www.globalmarketestimates.com/market-report/artificial-intelligence-in-oncology-drug-discovery-market-4062 Application Outlook (Revenue, USD Billion, 2020-2028) Target Identification Software & Services Pharmaceutical Companies & Biotechnology Companies
Aria Pharmaceuticals Frequently Asked Questions (FAQ)
When was Aria Pharmaceuticals founded?
Aria Pharmaceuticals was founded in 2014.
Where is Aria Pharmaceuticals's headquarters?
Aria Pharmaceuticals's headquarters is located at 265 Cambridge Ave, Palo Alto.
What is Aria Pharmaceuticals's latest funding round?
Aria Pharmaceuticals's latest funding round is Loan.
How much did Aria Pharmaceuticals raise?
Aria Pharmaceuticals raised a total of $13.87M.
Who are the investors of Aria Pharmaceuticals?
Investors of Aria Pharmaceuticals include Paycheck Protection Program, National Cancer Institute, Andreessen Horowitz, Softbank Ventures Asia, OS Fund and 4 more.
Who are Aria Pharmaceuticals's competitors?
Competitors of Aria Pharmaceuticals include Aitia, Cyclica, BERG, BenevolentAI, Exscientia and 7 more.
Compare Aria Pharmaceuticals to Competitors
Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.
Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
BioMap is a pioneer in the field of life science, specifically in the domain of artificial intelligence (AI) foundation models. The company's main service involves building AI foundation models to understand and predict the behavior of life at various scales of complexity, and to generate diverse proteins quickly and accurately. These models are primarily used in the life science industry, aiding in tasks such as drug discovery, early screening and diagnosis, and other precision medicine products. It was founded in 2020 and is based in Beijing, Beijing.